SCIENTIFIC INDUSTRIES (SCND) Company Report

Analyst Coverage

Research analysts covering SCIENTIFIC INDUSTRIES.

Latest news

Recent press releases and 8-K filings for SCND.

Scientific Industries Reports Q3 2025 Results and Strategic Focus

SCND

Earnings

Product Launch

M&A

Scientific Industries completed the divestiture of its legacy Genie products division in mid-August 2025, with the final installment of the sale price anticipated within the next three to six months.
The company is now focused on its Torbal division, which recently introduced an AI-driven feature to its VIVID workstation, and its bioprocessing segment, the latter facing a challenging market environment expected to continue into 2026.
Despite market challenges, Q3 2025 was the bioprocessing segment's strongest revenue quarter of the year, growing 50% above Q2 and marking the third consecutive quarter of sequential growth.
Significant progress was made on the DOTS platform, including the commercial launch of dissolved oxygen nanoparticles, with the first batch of 500 units entirely sold, and advancements in pH sensing technology for customer evaluations in Q1 2026.
The company is observing increasing strategic interest in its DOTS platform for data-driven bioprocessing and AI-enabled workflows, alongside growing OEM collaborations and strong customer loyalty.

Nov 20, 2025, 4:00 PM

Transcript

Scientific Industries Reports Q3 2025 Results, Highlights Divestiture and Bioprocessing Growth

SCND

M&A

Product Launch

Revenue Acceleration/Inflection

Scientific Industries completed the divestiture of its legacy Genie products division in mid-August 2025, focusing on a smooth transition and securing the final sale installment over the next three to six months.
The company introduced an AI-driven feature to its VIVID workstation to enhance customer insights, regulatory compliance, and cost savings.
In the bioprocessing segment, Q3 2025 was the strongest revenue quarter of the year, 50% above Q2, marking the third consecutive quarter of sequential growth, despite a challenging market environment.
Scientific Bioprocessing launched dissolved oxygen nanoparticles, expanding its market into buffered flasks, with the first batch of 500 units already sold.
The company continues to develop its DOTS platform, making solid R&D progress on biomass, dissolved oxygen, and pH sensing technologies, with pH sensing customer pilots planned for Q1 2026.

Nov 20, 2025, 4:00 PM

Transcript

Scientific Industries Reports Q3 2025 Results and Launches AI-Powered VIVID Feature

SCND

Earnings

Product Launch

M&A

Scientific Industries reported a net income of $3,994,400 and $0.34 earnings per share for the three months ended September 30, 2025, compared to a net loss of $1,180,100 and $(0.11) loss per share in the prior year period, primarily driven by a $5,263,400 gain on the sale of the Genie Division.
The company launched an AI-powered prescription label documentation and verification feature for its VIVID WORKSTATION.
VIVID product sales increased 27% year-over-year, and Torbal Division sales were up 15% year-over-year.
Cash, cash equivalents, and investments totaled $8.3 million as of September 30, 2025.
The launch of the second generation VIVID-ONE is scheduled for Q1 CY26.

Nov 20, 2025, 1:07 AM

Press Release

Scientific Industries discusses bioprocessing strategy and financial position at investor conference

SCND

Product Launch

New Projects/Investments

Guidance Update

Scientific Industries (SCND) has invested over $31,000,000 in its scientific bioprocessing business, which currently generates about $1,700,000 in revenue, with a target of $20,000,000 in sales at a 20% EBITDA and projected breakeven before the end of 2027.
The company reported a debt-free balance sheet with approximately $1.2 million in cash and cash equivalents as of March 31, 2025, and subsequently raised an additional $1.5 million in financing on April 18, 2025.
Scientific Industries plans to complete its fully integrated DOTS platform in 2025 by introducing new features such as an optical pH sensor and a high-performance liquid injection system before the end of the year.
A new sensor for baffled flasks is also expected to be introduced in the next several months, which is projected to quadruple the market opportunity for the company.

Aug 20, 2025, 3:42 PM

Scientific Industries Inc. Reports Second Quarter 2025 Financial Results

SCND

Earnings

M&A

Product Launch

Scientific Industries Inc. reported net revenues of $2.3 million for the second quarter ended June 30, 2025, a decrease from $2.6 million in the prior year period.
The company secured $10 million from the strategic divestiture of its Genie product line subsequent to quarter-end.
The Torbal Division saw an 11% increase in sales year-over-year, with VIVID sales specifically up 16% year-over-year.
Scientific Industries reported a net loss of $(1,522,700), or $(0.13) diluted earnings per share, for the three months ended June 30, 2025.
The VIVID machine learning pill counting system is on track for commercial launch in the first quarter of 2026, and a new dissolved oxygen sensor design is expected to launch in Q4.

Aug 19, 2025, 8:35 PM

Press Release

Scientific Industries Inc. sells Genie Division assets

SCND

M&A

Scientific Industries, Inc. (SCND) entered into an Asset Purchase Agreement on August 7, 2025, to sell substantially all assets of its Genie Division of Benchtop Laboratory Equipment to Troemner, LLC.
The purchase price for the Genie Division assets is $9,600,000, subject to working capital adjustments, with an additional earn-out of up to $1,500,000.
$1,140,000 of the earn-out is contingent on Scientific Industries, Inc. providing supply and transition services for the Genie products for an initial period of at least six months, renewable up to twelve months.
Following the sale, Scientific Industries, Inc. will continue to operate its Torbal Division of Benchtop Laboratory Equipment Operations.

Aug 11, 2025, 12:00 AM

8-K

Scientific Industries Divests Genie Division to Fund AI-Driven Growth

SCND

M&A

New Projects/Investments

Scientific Industries Inc. sold its Genie Division to Troemner, LLC, a manufacturing sister company of OHAUS Corporation, for $9.6 million in cash less working capital adjustments, plus up to $1.5 million in cash earnout over a twelve-month period.
This divestiture is part of a strategic refocus to transform Scientific Industries into a deep-tech, AI-enabling company.
The company will now concentrate on two core platforms: pharmacy automation with its VIVID platform and AI-enabled biomanufacturing with Scientific Bioprocessing's DOTS platform.
Proceeds from the sale, combined with over $27 million raised since 2020, will be reinvested to accelerate the growth of the Torbal Division (VIVID) and Scientific Bioprocessing platforms.